617 related articles for article (PubMed ID: 23060319)
1. Increasing trial efficiency by early reallocation of placebo nonresponders in sequential parallel comparison designs: application to antidepressant trials.
Boessen R; Knol MJ; Groenwold RH; Grobbee DE; Roes KC
Clin Trials; 2012 Oct; 9(5):578-87. PubMed ID: 23060319
[TBL] [Abstract][Full Text] [Related]
2. Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications.
Khin NA; Chen YF; Yang Y; Yang P; Laughren TP
J Clin Psychiatry; 2011 Apr; 72(4):464-72. PubMed ID: 21527123
[TBL] [Abstract][Full Text] [Related]
3. Dropout rates in placebo-controlled and active-control clinical trials of antipsychotic drugs: a meta-analysis.
Kemmler G; Hummer M; Widschwendter C; Fleischhacker WW
Arch Gen Psychiatry; 2005 Dec; 62(12):1305-12. PubMed ID: 16330718
[TBL] [Abstract][Full Text] [Related]
4. Does the presence of an open-label antidepressant treatment period influence study outcome in clinical trials examining augmentation/combination strategies in treatment partial responders/nonresponders with major depressive disorder?
Iovieno N; Papakostas GI
J Clin Psychiatry; 2012 May; 73(5):676-83. PubMed ID: 22569112
[TBL] [Abstract][Full Text] [Related]
5. Placebo-controlled, antidepressant clinical trials cannot be shortened to less than 4 weeks' duration: a pooled analysis of randomized clinical trials employing a diagnostic odds ratio-based approach.
Tedeschini E; Fava M; Papakostas GI
J Clin Psychiatry; 2011 Jan; 72(1):98-113. PubMed ID: 21208576
[TBL] [Abstract][Full Text] [Related]
6. Considering the case for an antidepressant drug trial involving temporary deception: a qualitative enquiry of potential participants.
Dowrick CF; Hughes JG; Hiscock JJ; Wigglesworth M; Walley TJ
BMC Health Serv Res; 2007 Apr; 7():64. PubMed ID: 17470280
[TBL] [Abstract][Full Text] [Related]
7. Correlation between different levels of placebo response rate and clinical trial outcome in major depressive disorder: a meta-analysis.
Iovieno N; Papakostas GI
J Clin Psychiatry; 2012 Oct; 73(10):1300-6. PubMed ID: 23140647
[TBL] [Abstract][Full Text] [Related]
8. An examination of the efficiency of the sequential parallel design in psychiatric clinical trials.
Tamura RN; Huang X
Clin Trials; 2007; 4(4):309-17. PubMed ID: 17848492
[TBL] [Abstract][Full Text] [Related]
9. Optimality, sample size, and power calculations for the sequential parallel comparison design.
Ivanova A; Qaqish B; Schoenfeld DA
Stat Med; 2011 Oct; 30(23):2793-803. PubMed ID: 21805484
[TBL] [Abstract][Full Text] [Related]
10. Optimizing trial design in pharmacogenetics research: comparing a fixed parallel group, group sequential, and adaptive selection design on sample size requirements.
Boessen R; van der Baan F; Groenwold R; Egberts A; Klungel O; Grobbee D; Knol M; Roes K
Pharm Stat; 2013; 12(6):366-74. PubMed ID: 24214896
[TBL] [Abstract][Full Text] [Related]
11. Factors that influence the outcome of placebo-controlled antidepressant clinical trials.
Niklson IA; Reimitz PE; Sennef C
Psychopharmacol Bull; 1997; 33(1):41-51. PubMed ID: 9133750
[TBL] [Abstract][Full Text] [Related]
12. A new population-enrichment strategy to improve efficiency of placebo-controlled clinical trials of antidepressant drugs.
Merlo-Pich E; Alexander RC; Fava M; Gomeni R
Clin Pharmacol Ther; 2010 Nov; 88(5):634-42. PubMed ID: 20861834
[TBL] [Abstract][Full Text] [Related]
13. Bayesian modelling and ROC analysis to predict placebo responders using clinical score measured in the initial weeks of treatment in depression trials.
Gomeni R; Merlo-Pich E
Br J Clin Pharmacol; 2007 May; 63(5):595-613. PubMed ID: 17488364
[TBL] [Abstract][Full Text] [Related]
14. The efficacy profile of vilazodone, a novel antidepressant for the treatment of major depressive disorder.
Reed CR; Kajdasz DK; Whalen H; Athanasiou MC; Gallipoli S; Thase ME
Curr Med Res Opin; 2012 Jan; 28(1):27-39. PubMed ID: 22106941
[TBL] [Abstract][Full Text] [Related]
15. Signal detection and placebo response in schizophrenia: parallels with depression.
Mallinckrodt CH; Zhang L; Prucka WR; Millen BA
Psychopharmacol Bull; 2010; 43(1):53-72. PubMed ID: 20581800
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of performance of some enrichment designs dealing with high placebo response in psychiatric clinical trials.
Chen YF; Yang Y; Hung HM; Wang SJ
Contemp Clin Trials; 2011 Jul; 32(4):592-604. PubMed ID: 21540126
[TBL] [Abstract][Full Text] [Related]
17. Exploratory analyses of efficacy data from schizophrenia trials in support of new drug applications submitted to the US Food and Drug Administration.
Khin NA; Chen YF; Yang Y; Yang P; Laughren TP
J Clin Psychiatry; 2012 Jun; 73(6):856-64. PubMed ID: 22687813
[TBL] [Abstract][Full Text] [Related]
18. Complementary and alternative medicine for major depressive disorder: a meta-analysis of patient characteristics, placebo-response rates, and treatment outcomes relative to standard antidepressants.
Freeman MP; Mischoulon D; Tedeschini E; Goodness T; Cohen LS; Fava M; Papakostas GI
J Clin Psychiatry; 2010 Jun; 71(6):682-8. PubMed ID: 20573327
[TBL] [Abstract][Full Text] [Related]
19. Relative efficiency and sample size for cluster randomized trials with variable cluster sizes.
You Z; Williams OD; Aban I; Kabagambe EK; Tiwari HK; Cutter G
Clin Trials; 2011 Feb; 8(1):27-36. PubMed ID: 21163852
[TBL] [Abstract][Full Text] [Related]
20. Last-observation-carried-forward imputation method in clinical efficacy trials: review of 352 antidepressant studies.
Woolley SB; Cardoni AA; Goethe JW
Pharmacotherapy; 2009 Dec; 29(12):1408-16. PubMed ID: 19947800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
